Glaxosmithkline Stock News

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more fu

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address. Pharmaceutical Companies : In 2016, then- Vice President Biden launched the Cancer Moonshot program the help boost spending on medical research to take on various types of cancer. In 2022, Biden announced plans to boost spending and reduce the death rate from cancer by 50% over the next 25 years. The Partnership for Accelerating Cancer Therapies includes 11 companies working to boost treatments for various types of cancers. The companies are AbbVie Inc (NYSE: ABBV ), Amgen Inc (NASDAQ: AMGN ), Boehringer-Ingelheim Pharma , Bristol-Myers Squibb Co (NYSE: BMY ), Celgene (owned by Bristol-Myers Squibb), Genetech (owned by Roche ), Gilead Sciences (NASDAQ: GILD ), GlaxoSmithKline (NYSE: GSK ), Janssen Research (owned by Johnson & Johnson (NYSE: JNJ )), Novartis (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Pfizer Inc (NYSE: PFE ).

Shares of Pfizer Inc. gained 0.6% in premarket trading on Wednesday after the company said its experimental respiratory syncytial virus (RSV) vaccine had received a breakthrough therapy designation from the Food and Drug Administration. The vaccine candidate is being evaluated in pregnant women to see if it can prevent illness among infants up to until the age of 6 months old. Several drug makers are developing RSV vaccines, including Moderna Inc. and GlaxoSmithKline , though GSK this week halted a study assessing its investigational RSV shot in pregnant women, saying it needs to better understand the safety data. Pfizer''s stock has gained 36.5% over the past year, while the broader S&P 500 is up 10.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 51.5 and 45.64 with a mean TP of 48.57. With the stocks previous close at 41.86 this now indicates there is a potential upside of 16.0%. The 50 day MA is 44.16 and the 200 day MA is 41.31. The company has a market capitalisation of $105,612m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets=GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $122,541m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

Las Vegas, USA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Dengue Fever Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight Dengue Fever Pipeline constitutes 20+ key companies continuously working towards developing 20+ Dengue Fever treatment therapies, analyzes DelveInsight DelveInsight''s ‘ Dengue Fever Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Dengue Fever pipeline domain. Some of the essential takeaways from the Dengue Fever Pipeline report: DelveInsight''s Dengue Fever Pipeline analysis depicts a robust space with 20+ active players proactively working to develop 20+ pipeline treatment therapies. Some of the key Dengue companies working to develop potential drug candidates to improve the Dengue Fever treatment scenario include Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and many others.

GlaxoSmithKline Plc (NYSE: GSK ) has halted enrollment and vaccination in three trials of its experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women. Last week, GSK paused a late-stage trial , dubbed "GRACE," as well as two … Full story available on Benzinga.com

Haleon, which makes brands including Sensodyne toothpaste, expects annual sales growth of between 4% and 6% in 2022.

On Monday, GlaxoSmithKline (GSK) announced it would carry out the proposed demerger and listing of its consumer healthcare business in July.Following a shareholder vote for approval,…

GlaxoSmithKline (GSK) has paused more trials of its potential respiratory syncytial virus ((RSV)) vaccine candidate in pregnant women, after certain trials were paused earlier this…

On Thursday, the Canadian government approved the use of Covifenz, the world’s first plant-based COVID-19 vaccine, jointly developed by Medicago Inc., a biopharma company owned by Mitsubishi Chemical and Philip Morris, situated in Quebec City, and GlaxoSmithKline Plc.

A protein-based vaccine that GlaxoSmithKline and Sanofi hope to get approved has several advantages over mRNA-based vaccines made by companies like Moderna and Pfizer.

Watch Video European drugmakers Sanofi and Glaxosmithkline (GSK) released data showing their COVID vaccine is 100% effective at keeping patients out of the hospital. It has not been independently scientifically reviewed. Drugmakers Sanofi and GlaxoSmithKline have asked the Food and Drug Administration for emergency use authorization of their vaccine. "We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," Roger Connor, president of GSK, said in a statement. Sanofi''s and GSK''s vaccine is based on a more conventional protein-based vaccine technology. It''s a recombinant protein vaccine, which means it recombines different segments of DNA. This uses DNA from the SARS-COV-2 spike protein, which COVID needs to enter and infect healthy cells. The combined DNA helps fire up your immune response. This is different from Pfizer and Moderna''s mRNA, or messenger RNA, technology. That vaccine uses a genetic code to teach the body''s cells how to make proteins that trigger immune responses.

Several former scientists and staff from companies like Johnson & Johnson (NYSE: JNJ ), GlaxoSmithKline (NYSE: GSK ) and Schiff Nutrition are bringing a new delivery platform to market that boosts the bioavailability of hemp cannabidiol or CBD . According to the company, NextEvo, its SmartSorb technology not only turns oil-based CBD ingredients into water-soluble ingredients but also enables a higher load of active CBD ingredients. “SmartSorb turns premium, hemp-derived CBD, which is usually oil-soluble, into a water-soluble–like (water-dispersible) emulsion and delivers the equivalent of four times the amount of CBD in oil-based formulations,” … Full story available on Benzinga.com

As Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline Plc''s (NYSE: GSK ) COVID-19 vaccine finally heads to regulators, another shot using GSK''s pandemic adjuvant has won its first global approval . Mitsubishi Tanabe Pharma Corporation -backed Medicago''s recombinant COVID-19 vaccine, dubbed Covifenz, has snagged a green light in Canada in individuals 18 to 64 years of age. The vaccine uses a plant-based virus-like particles technology to mimic … Full story available on Benzinga.com